NEW YORK - Sequenom Inc. shares climbed in premarket trading Wednesday after the company said its Downs syndrome screening test was effective in 200 cases, with no false positives or false negatives.
NEW YORK - Sequenom Inc. shares climbed in premarket trading Wednesday after the company said its Downs syndrome screening test was effective in 200 cases, with no false positives or false negatives.